{"id":690255,"date":"2022-09-29T08:34:35","date_gmt":"2022-09-29T12:34:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/"},"modified":"2022-09-29T08:34:35","modified_gmt":"2022-09-29T12:34:35","slug":"phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/","title":{"rendered":"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MARLBOROUGH, Mass.<\/span>, Sept. 29, 2022<\/span> \/PRNewswire\/ —\u00a0Phio Pharmaceuticals\u00a0Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL\u2122<\/sup>) therapeutic platform, today announced the appointment of Robert Bitterman<\/span> as interim Executive Chairman of the Board of Directors (the “Board”). As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company’s operations. Mr. Bitterman has served as a director on the Company’s Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles.<\/p>\n

Logo – https:\/\/mma.prnewswire.com\/media\/786567\/Phio_Pharmaceuticals_Logo.jpg<\/a><\/p>\n

The Company is also pleased to announce the appointment of Robert Ferrara<\/span> as Lead Independent Director of the Board.\u00a0 Mr. Ferrara currently serves as the Chairman of the Audit Committee of the Board. With his appointment, Mr. Ferrara will assume the duties and responsibilities of Lead Independent Director. Mr. Ferrara has served as a director on the Company’s Board since 2019 and has held numerous senior executive level financial positions in both domestic and international public and private companies in a variety of industries, including pharmaceuticals and life sciences. Mr. Ferrara is\u00a0a Certified Public\u00a0Accountant and earned a BS degree in accounting from Lehigh University<\/span>.<\/p>\n

\n About\u00a0Phio Pharmaceuticals Corp.<\/b>\n <\/p>\n

Phio Pharmaceuticals Corp.\u00a0(Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL\u2122<\/sup>) therapeutic platform. The Company’s efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company’s goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company’s website,\u00a0www.phiopharma.com<\/a>.<\/p>\n

\n Contact\u00a0Phio Pharmaceuticals Corp<\/b>.
ir@phiopharma.com<\/a>\u00a0<\/p>\n

\n Investor Contact
<\/b>Ashley R. Robinson\u00a0
LifeSci Advisors
arr@lifesciadvisors.com<\/a>\u00a0<\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman-301636146.html<\/a><\/p>\n

SOURCE Phio Pharmaceuticals Corp.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MARLBOROUGH, Mass., Sept. 29, 2022 \/PRNewswire\/ —\u00a0Phio Pharmaceuticals\u00a0Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL\u2122) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the “Board”). As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company’s operations. Mr. Bitterman has served as a director on the Company’s Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles. Logo – https:\/\/mma.prnewswire.com\/media\/786567\/Phio_Pharmaceuticals_Logo.jpg The … <\/p>\n

Continue reading “Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690255","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPhio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MARLBOROUGH, Mass., Sept. 29, 2022 \/PRNewswire\/ —\u00a0Phio Pharmaceuticals\u00a0Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL\u2122) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the “Board”). As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company’s operations. Mr. Bitterman has served as a director on the Company’s Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles. Logo – https:\/\/mma.prnewswire.com\/media\/786567\/Phio_Pharmaceuticals_Logo.jpg The … Continue reading "Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T12:34:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE87320&sd=2022-09-29\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman\",\"datePublished\":\"2022-09-29T12:34:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/\"},\"wordCount\":373,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE87320&sd=2022-09-29\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/\",\"name\":\"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE87320&sd=2022-09-29\",\"datePublished\":\"2022-09-29T12:34:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE87320&sd=2022-09-29\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE87320&sd=2022-09-29\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/","og_locale":"en_US","og_type":"article","og_title":"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman - Market Newsdesk","og_description":"PR Newswire MARLBOROUGH, Mass., Sept. 29, 2022 \/PRNewswire\/ —\u00a0Phio Pharmaceuticals\u00a0Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL\u2122) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the “Board”). As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company’s operations. Mr. Bitterman has served as a director on the Company’s Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles. Logo – https:\/\/mma.prnewswire.com\/media\/786567\/Phio_Pharmaceuticals_Logo.jpg The … Continue reading \"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T12:34:35+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE87320&sd=2022-09-29","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman","datePublished":"2022-09-29T12:34:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/"},"wordCount":373,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE87320&sd=2022-09-29","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/","name":"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE87320&sd=2022-09-29","datePublished":"2022-09-29T12:34:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE87320&sd=2022-09-29","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE87320&sd=2022-09-29"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690255"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}